Goal to end Aids by 2030 ‘more off-track' after Trump cuts, UNAids head says

The US administration's decision to axe swathes of US foreign aid has disrupted the supply of life-saving HIV treatments. PHOTO: REUTERS
JOHANNESBURG – US President Donald Trump's cuts to HIV/Aids programmes will further derail an already faltering plan to end the disease as a public health threat by 2030, UNAids executive director Winnie Byanyima said on June 13.
With 1.3 million new infections in 2023, according to the latest data, the world was already 'off track', Ms Byanyima told journalists in South Africa, the country with the world's largest number of people living with human immunodeficiency virus (HIV), at eight million.
'Less funding means we will get more and more off-track,' she said in the main city of Johannesburg, after meeting South African President Cyril Ramaphosa to discuss Africa's HIV/Aids (acquired immune deficiency syndrome) strategy in light of the US president slashing billions of dollars in foreign aid in February.
'We don't know yet what that impact will be, but impact – there will be... already, you see in several countries a drop in the number of people going to clinics,' Ms Byanyima said.
Before the cuts, prevention programmes had brought down new infections, she said, but they were 'not coming down fast enough to reach our target of 2023'.
Now, with the shuttering of community prevention clinics across Africa, infections would surely rise, though it was not clear yet by how much, she said.
The administration's decision to axe swathes of US foreign aid has disrupted the supply of life-saving HIV treatments, with some countries potentially running out. In South Africa, about a fifth of whose HIV budget was US-funded, testing and monitoring of HIV patients is already falling.
Ms Byanyima said even poor, indebted countries were managing to plug funding gaps, but called on other rich nations to step in.
'We're saying to the donors: this is one of the diseases... without a cure, without a vaccine, yet we're seeing progress,' she said. 'If you've got a good success story, why drop it... before you end it?' REUTERS
Join ST's Telegram channel and get the latest breaking news delivered to you.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Straits Times

10 hours ago

• Straits Times

French scientists find new blood type in Guadeloupe woman

A woman from the Caribbean island of Guadeloupe is the only known carrier of a new blood type, dubbed 'Gwada negative". PHOTO: ISTOCKPHOTO BASSE-TERRE - A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed 'Gwada negative', France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on June 20. 'The EFS has just discovered the 48th blood group system in the world!' the agency said, in a statement on social network LinkedIn. 'This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT).' The scientific association had until now recognised 47 blood group systems. Dr Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a 'very unusual' antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to 'high-throughput DNA sequencing', which highlighted a genetic mutation, Dr Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Dr Peyrard said. This woman 'is undoubtedly the only known case in the world,' said the expert. 'She is the only person in the world who is compatible with herself,' he said. Dr Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name 'Gwada negative', which refers to the patient's origins and 'sounds good in all languages', has been popular with the experts, said Dr Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing, the discovery of new blood groups has accelerated in recent years. Dr Peyrard and colleagues are now hoping to find other people with the same blood group. 'Discovering new blood groups means offering patients with rare blood types a better level of care,' the EFS said. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.

Straits Times

19 hours ago

• Straits Times

The Wegovy effect: A weight-loss drug reshapes the lives of US teens battling obesity

(Clockwise from left) Austin Smith and his mother, Katie Duncan and Stephanie Serrano are among young people using Wegovy for weight loss. PHOTOS: REUTERS High-school freshman Austin Smith sank into depression from the merciless teasing and bullying he endured from his classmates over his weight. By age 15, Katie Duncan felt unhealthy and self-conscious from the excessive weight she carried, but couldn't tame the incessant food cravings caused by a tumor that had damaged part of her brain. Ms Stephanie Serrano, diagnosed with type 2 diabetes and liver disease related to her obesity, stopped attending high school in person and became a virtual shut-in after years of failed dieting. For these teens, obesity had become a painful physical and emotional burden, the persistent social stigma of their condition isolating them from their peers, and they were frustrated by their inability to lose weight. That's why, with support from their parents, they joined a small but fast-growing cohort of American teens who have chosen to take Novo Nordisk's weight-loss drug Wegovy, placing them at the forefront of a monumental shift in the treatment of childhood obesity. As childhood obesity rates soared in recent decades to epidemic levels, pediatricians could offer children and their families little beyond the conventional – and often ineffective – counsel of healthier diets and more exercise. That changed in December 2022, when US regulators approved Wegovy, which has become a multibillion-dollar seller for treating obesity in adults, for children 12 and older. Since then, teenagers have been starting on Wegovy at quickly rising rates, as Reuters recently reported. Still, based on those rates, the overall numbers remain small – fewer than 100,000 – next to the roughly 8 million, or one in five, American teens living with obesity. Those who have embraced the treatment, including the American Academy of Pediatrics, say Wegovy gives adolescents a chance at a healthier future by reducing their risk of developing type 2 diabetes, liver disease and other debilitating, and costly, chronic illnesses. They say weight loss can also ease the harm of the teasing and social isolation teens with obesity often endure. Some doctors, though, are hesitant to prescribe the drug, citing the lack of long-term safety data, concerns that children won't get adequate nutrition while taking it, and the possibility that it could cause eating disorders. Their caution is echoed in statements by US Health Secretary Robert F. Kennedy Jr., who has criticised the 'overmedicalisation of our kids' and emphasises the role of healthier food in combating chronic disease. That split leaves families to consider for themselves the potential benefits and risks of Wegovy when deciding on a course of treatment for a child with obesity. For this article, Reuters reporters found children who had taken Wegovy or a similar weight-loss drug to speak with them about their experiences. The reporters spent more than a year closely following four teens and their families to examine in detail the impact of treatment. Here are their stories: 'I can't wait' GLADSTONE, Missouri – 'Why do you want to lose weight?' When Ms Elizabeth Smith asked her son Austin that question, he didn't hesitate. 'To be healthier and so people will stop bullying me,' he said. Elizabeth wrote his answer on the form she was filling out as they waited in the doctor's office. Austin was near the end of a miserable freshman year. At almost 300 pounds, he struggled each morning to squeeze down the aisle of the school bus. Other students teased him relentlessly. He looked pregnant, they said, and he was gross. At school, the insults continued. He found solace in woodworking class, where he could focus on his projects and tune out the taunts – until the day a classmate cornered him, jammed a power drill into his long, curly hair and turned it on, leaving the tool dangling from a messy tangle. Ms Elizabeth Smith tousles the hair of her son, Austin Smith, who uses Wegovy for weight loss. PHOTO: REUTERS Even before his parents learned about that incident, they knew something was wrong. Austin, who has a mild form of autism, had grown increasingly withdrawn and rarely left his bedroom, where his mother found him sobbing after school several times. 'I can't make any friends,' Austin told her. They feared he might contemplate suicide. They decided to seek medical help. A psychiatrist put Austin on an anti-depressant. Ms Elizabeth thought the obesity specialist who had been treating her could help, too. Five weeks earlier, Dr Matt Lindquist at University Health in Kansas City, Missouri, near their home in suburban Gladstone, had started her on Wegovy, and she had already dropped 20 pounds, to around 220. That's how Austin and Ms Elizabeth found themselves filling out forms in Dr Lindquist's office in April 2023. Four months earlier, US regulators had approved Wegovy for teens with obesity, defined as a body mass index at or above the 95th percentile for children of the same age and sex. The doctor judged Austin, then 15 years old, to be in good overall health and a good candidate for Wegovy. The drug would tame the constant hunger Austin described. Dr Lindquist told Austin that after starting on Wegovy, he should cut his meal portions in half and eat more healthy proteins and vegetables. Even then, the doctor said, Austin might experience the common side effects of nausea and vomiting. Out of pocket, the more than US$1,000 ($1,286)-a-month cost of Wegovy would have been unaffordable. The Smiths live paycheck to paycheck on Ms Elizabeth's pay as a hospital billing clerk at University Health and what her husband, Jeremy, earns building courtroom exhibits. But Ms Elizabeth's employer-sponsored health insurance covered Wegovy. About a month after the visit with Dr Lindquist, the first box of Austin's Wegovy injections arrived. Ms Elizabeth, fearing Austin would get sick in class, asked him to wait to start the drug until after the school year ended in a week. 'I can't wait,' Austin said. She gave him his first injection that night. The effect was almost immediate. He used to come home from school and devour dozens of chicken nuggets while playing video games. Now, he felt full far sooner. Many nights, he stayed in his room at dinnertime. 'I felt a little bad because I couldn't eat my parents' cooking,' Austin said. The only side effect he experienced was a little stomach upset. Elizabeth began keeping a log of Austin's weight. At the start of his sophomore year, two months after starting Wegovy, Austin had lost 23 pounds. That's when he first noticed the difference: On the school bus that morning, he didn't bump into the seats while walking down the aisle. 'I was so happy to go home and tell my parents about it,' he said. In early September 2023, Dr Lindquist increased Austin's weekly dose of Wegovy to the maximum, 2.4 milligrams, as recommended on the label. Austin started vomiting after eating. Dr Lindquist cut the dose back to the previous 1.7 milligrams. The vomiting subsided. Austin reveled in his altered appearance, and his mood lightened. He told Ms Elizabeth the bullying had stopped. He liked to stand in his now billowing marching band uniform and pull the waistband outward to reveal gaping spaces. He was back to tending his oregano, thyme and other herbs growing in pots outside the front door. He played in the backyard with his puggle, Lucy, or one of his family's other two dogs. He spent weekends hanging out with his best friend, an elderly man in the neighborhood, gardening, walking their dogs and watching movies. In October 2023, five months into treatment, Austin was down to 232 pounds. Ms Elizabeth wrote Dr Lindquist to ask about his target weight for Austin. The doctor responded that he didn't set weight goals, preferring to focus on a patient's overall health, and was encouraged by Austin's progress. 'I would say he likely needs meds lifelong to support a healthy weight,' the doctor wrote. Ms Elizabeth's heart sank. 'I wouldn't want him to be on this for a lifetime,' she said. Austin didn't share those qualms. 'Before, I would look in the mirror and hate myself and wish I could be an entirely different person,' he said. 'Now I feel like I can accept myself a bit more.' He had dropped to 222 pounds by early December 2023. One Saturday, he came into the kitchen and lifted his shirt to show his family his now-visible ribs. For Christmas, Ms Elizabeth bought him extra-large pants and shirts to replace his 2XL clothes. 'He's like a whole new person,' his pediatrician told Ms Elizabeth, echoing many family friends and relatives. Austin's father was cheered by his son's physical and emotional transformation. Jeremy had lost about 30 pounds while taking Ozempic, Novo's medication for type 2 diabetes that has the same active ingredient as Wegovy. At a January 2024 appointment, Dr Lindquist chided Austin when he admitted to skipping meals. 'You need to put gas in your tank to make it go,' the doctor told him. He referred the teen to a nutritionist. Ms Elizabeth scheduled an appointment, but had to cancel because of a work conflict and hasn't booked a new visit. The following April, Austin was at 200 pounds. He celebrated the end of his sophomore year by taking a trip in June to Belize with other students. He snorkeled and went on eight different zip-lines through the rainforest. The weight limit for riding the zip-lines was 280 pounds. Back home, Ms Elizabeth wept when she watched the video Austin shared of him gliding through the trees. 'He couldn't have done this before,' she said. Soon after his return, he was hit hard by the death of his elderly friend. His psychiatrist prescribed a more powerful anti-depressant. Austin then panicked when, after Dr Lindquist stretched out Austin's dosages, he started eating more and putting on pounds. That stopped when he went back to regular weekly injections. The family got another shock in January, when Ms Elizabeth's insurance through University Health quit covering Wegovy and other so-called GLP-1 drugs for weight loss. Wegovy had been free, after insurance and Novo-provided coupons. Now, the health system would be providing Wegovy at US$250 for a three-month supply through its own pharmacy. Insurance coverage for Wegovy has steadily expanded since the drug's 2021 launch, and Novo has offered ways to bring down out-of-pocket costs. But employers and government agencies often impose restrictions to hold down costs associated with the drug's high price and the large number of patients eligible to take it. In 2024, 64 per cent of US employers with 20,000 or more workers covered GLP-1 drugs for obesity, up from 56 per cent in 2023, according to Mercer, a benefits consulting firm. Medicare and most state Medicaid programs don't cover the drugs solely for weight loss. Ms Elizabeth has been able to scrape together enough to cover the cost. She also had to find Austin another doctor at University Health after Dr Lindquist left to set up his own practice and the hospital stopped covering Wegovy for doctors outside of its network. Austin is just relieved that his parents can afford to keep his prescription going. His weight has leveled off at about 200 pounds – a 30 per cent loss in two years. He doesn't want to contemplate life without Wegovy. 'I feel I would be bigger,' he said. 'I don't want to go back.' 'What I'm doing isn't working' WILMINGTON, Delaware – At 15, Katie Duncan, 6-foot-1 and 270 pounds, was growing increasingly anxious and depressed about her weight. Some of her clothes no longer fit, she was easily winded while walking, and her back ached. Classmates occasionally lobbed mean comments about her size. Blood tests showed she had high triglyceride levels, which can increase the risk of stroke and heart disease. But Katie's hunger never let up. She often ate four or five meals a day. She would devour an entire pizza and hide snacks in her bedroom to satisfy cravings. She had tried an older weight-loss drug that did nothing. 'We need to change something,' she told her father, Randy, in the summer of 2023. 'What I'm doing isn't working.' Ms Katie Duncan uses Wegovy for weight loss. PHOTO: REUTERS Randy scheduled an appointment at the Healthy Weight and Wellness Clinic at the nearby Nemours Children's Hospital. The Duncans knew the hospital well: Katie had been treated there after she was diagnosed at age seven with a brain tumor. Doctors had given her a 20 per cent chance of surviving the cancer. Katie took an experimental drug and underwent months of chemotherapy and radiation. She was tiny at the time, only 42 pounds. The cancer went into remission within a year. However, the tumor had damaged her hypothalamus, the portion of the brain that controls hunger, and the nearby pituitary gland, which releases hormones that regulate growth and metabolism, among other key functions. Her doctors put her on a lifelong regimen of synthetic hormones and a low-dose steroid to replace what she lost. The brush with death forged a fierce bond between father, divorced since Katie was 3, and daughter, the youngest of five siblings and the only one still living at home. Randy, a paramedic and volunteer firefighter, took off from work to go to every doctor's appointment and physical therapy session with her. Katie treasured a locket with her father's photo inside and refused to go to school without it. He accompanied her on every school field trip. Katie tried a sleepaway camp hosted by the hospital and called her dad to pick her up after the first night. 'I don't like being away from my family,' she said. But by the time Katie was 9, Randy, now remarried, noticed something was wrong. Katie was constantly hungry, and the two clashed repeatedly over it. During a trip to SeaWorld in Florida, they shouted at each other when Katie complained that she was starving, even after a big breakfast at their hotel. Katie steadily put on weight during her middle-school years. She avoided running and other sports due to painful neuropathy in her feet, likely caused by her cancer and chemotherapy. She couldn't keep pace with classmates in physical education. At her appointment in 2023, Katie saw Dr Thao-Ly Phan, medical director of the Nemours weight clinic. After examining Katie and reviewing her medical history, Dr Phan determined that Katie probably has 'hypothalamic obesity' from her brain injury, for which the replacement hormones don't fully compensate. 'Her body isn't helping her out,' Dr Phan said. While brain cancer isn't common, Dr Phan said, teens can have other, more common underlying conditions or treatments that lead to obesity and complicate their care. For example, polycystic ovary syndrome can cause hormonal imbalances and weight gain, especially around the belly, in young women. Antidepressants, mood stabilisers and other psychiatric medications can lead to weight gain, too. After prescribing Wegovy, Dr Phan had Katie see the clinic's psychologist and nutritionist, a routine step the doctor requires of her patients. 'We don't want kids to lose so much weight that they develop eating disorders,' she said. 'We want to make sure that they're still getting the nutrition they need to grow and to thrive.' Katie got her first dose of Wegovy in November 2023. She lost about 20 pounds in the first couple months, with only mild side effects. At times, Katie had no interest in eating and skipped meals, despite Dr Phan's warnings not to. Poor nutrition and eating habits during adolescence can have long-term consequences, from impairing cognitive development to increasing the risk of osteoporosis and bone fractures, research shows. About six months after Katie started treatment, the family's insurer cut off coverage of her Wegovy. Randy's appeal of that decision failed, and he switched Katie's prescription to her secondary insurance with the state Medicaid program, which had been in place since her cancer treatment. Delaware is one of 14 states with Medicaid coverage for the newer GLP-1 weight-loss drugs. Katie missed only one weekly dose. At an appointment with Dr Phan in March, Katie weighed 209 pounds, down 60, or 22 per cent of her body weight, in about 18 months. Her triglycerides were no longer elevated. The weight loss has brought welcome changes. Katie said she used to lack motivation to do much at all and would lounge for hours in bed. 'I used to always feel yucky before,' she said. 'The weight loss has actually helped a lot with my energy.' The 17-year-old now enjoys regular visits to the Planet Fitness gym with her father and stepmother, Denise, and spends more time on her painting and crafts. She has more stamina to cook two hours straight in her high-school culinary class. She also doesn't get winded chasing after her two-year-old niece at family gatherings. While she used to hide herself in baggy clothes, she now feels comfortable wearing sundresses. Randy is pleased with Katie's progress. He worries that Delaware may stop covering GLP-1 weight-loss drugs through Medicaid due to budget shortfalls or proposed cuts in federal funding. California and North Carolina are seeking to rescind Medicaid coverage of the drugs to save millions of dollars. 'I hope to God they keep Wegovy around for kids,' Randy said. Katie wants to stay on the drug and trusts that her dad and her doctor wouldn't let her take anything harmful. 'Wegovy doesn't scare me,' she said. 'I've had so many needles in my life.' 'I'll do whatever it takes' DODGE COUNTY, Wisconsin – Early in 2024, after eight months on Wegovy, Leo had a choice to make. He could stop taking the drug, end the side effects that were wreaking havoc on his life and risk regaining some of the more than 25 pounds he had lost. Or he could stay on it, keep losing weight and hope the severe stomach aches, nausea and diarrhea would abate. For this article, Leo and his mother, Jamie, asked Reuters to withhold details such as their precise location and Leo's surname, and Leo declined to be photographed. They said they feared the exposure would lead to more teasing from Leo's peers about his appearance and his decision to take a weight-loss drug. Leo had been a strong candidate for Wegovy when he first saw an obesity specialist, Dr Leslie Golden, in mid-2023. He was a compulsive eater from an early age, due in part to his attention-deficit/hyperactivity disorder, for which he takes medication. He was diagnosed with obesity at 11 years old. Three years later, he was carrying 181 pounds on his 5-foot-4 frame. Jamie tried to stock the kitchen with healthier foods. But Leo's older sister and two older stepbrothers wanted ultra-processed snacks and sugary drinks around. Leo would gulp down five cans of Coke in a day. He sneaked snacks and sodas into his bedroom at night, leaving empty wrappers and cans for his mother to find strewn about the next morning. One of his stepbrothers was severely underweight, complicating Jamie's food choices for the family. The teasing and bullying started in middle school. When he walked the halls between classes, other students hurled jeers and jokes at him. 'It was always directed at my weight,' he said. 'The comments just got to me.' Leo knew he had a problem but felt powerless to do anything about it. 'I was eating way too much,' he said. 'I was worried I was going to get way too overweight.' Jamie, a pharmacist, thought Wegovy might help. Frustrated with her own efforts to lose weight, she had started taking the drug in January 2022. She, like Leo after her, suffered severe gastrointestinal side effects, but they faded, and after a year, she had lost 50 pounds. Leo, having learned what Wegovy did for his mother, was open to trying it. In June 2023, Leo had his first appointment with Dr Golden, at her obesity clinic in a town near where he and his family live about an hour outside Milwaukee, Wisconsin. He already bore troubling signs of the effects of his obesity. His blood pressure was high. His elevated blood sugar level put him at increased risk for type 2 diabetes. The doctor worried that Leo could develop liver and heart disease if he didn't lose weight. She prescribed Wegovy. Dr Golden doesn't require families to undergo counseling on lifestyle changes as a prerequisite for prescribing the drug for children. She said most families have already tried other ways to lose weight before they reach her office, and imposing a months-long delay before drug therapy 'is really just another form of bias and stigma'. She does ask for monthly visits so she can monitor a child's progress. Her patients pick three goals for the coming month – for nutrition, movement and behavior. For Leo, at one point, that meant eating more carrots and cauliflower, playing basketball in the driveway and downing fewer sugary drinks. Soon, Leo was eating a lot less, though what he ate didn't change so much. At restaurants, he could stomach only three bites of the double cheeseburgers he usually ordered. He was happy with the weight he was losing. The bullying was easing up, and some classmates even complimented him on looking thinner. He grew comfortable raising his hand in class. 'It feels pretty good to get myself out there,' he said. But as his doses steadily increased – the standard of care for GLP-1 medicines is to up the dose every four weeks – the side effects started taking a toll. He took medicines to quell the nausea and diarrhea. He dropped off anti-diarrhea pills with the school nurse. Some days, his stomach upset was so bad that Jamie had to pick him up at lunchtime. Leo was experiencing by far the most common side effects of Wegovy. In the largest clinical trial of the medicine on teens, 62 per cent of patients experienced nausea, vomiting and diarrhea. Most reported mild to moderate side effects that lasted two to three days. Since their launch, Wegovy and other GLP-1 drugs have also been associated with much rarer incidents of gastric paralysis, pancreatitis, depression and blindness. As his absences piled up, Leo's grades suffered, and he grew moodier. At a parent-teacher conference in October 2023, teachers told Jamie that Leo had become more withdrawn in class. At a checkup with his regular pediatrician later that month, his answers on a questionnaire indicated depression. The doctor prescribed an antidepressant. That didn't lessen the side effects, though, and Leo's school absences persisted. In February 2024, the high school notified his mother that he had missed 10 days, the maximum allowed for the year. Soon after that is when Dr Golden presented Leo with the choice about continuing with Wegovy. Jamie favored sticking with the drug. The doctor wanted the choice to be Leo's. 'Jamie is a very involved parent who wants to protect and do what's best for him,' Dr Golden later told Reuters. 'I had to really zone in on Leo: Do you want to keep taking this?' Despite the physical pain and discomfort, the problems at school, the depression, Leo was adamant. 'I'll do whatever it takes,' Leo told Dr Golden. 'No matter how sick I get, I don't want to stop.' Several weeks later, the side effects began to ease. By last summer, Leo had dropped under 150 pounds. His waist had shrunk by five inches. Based on his body mass index, he no longer had obesity. 'I am happy that I don't get called names anymore,' Leo said. Then last autumn, he started to put on weight. Dr Golden had reminded Leo that some additional weight was expected as he grew three inches taller over the span of a year, eventually reaching 5 foot 7. But Leo's mother found food wrappers and soda cans in his bedroom. In November 2024, Leo wept when he stepped on the scale at home and saw that he had gained 14 pounds, up to 164. 'I'm getting fat again,' he told his mother. At an appointment with Dr Golden the following month, the doctor put Leo on the highest weekly dose of Wegovy to help counter his cravings. That worked, without the side effects he had experienced earlier. At a checkup in April, Leo weighed 154 pounds, down nearly 30 pounds in the past two years. Leo took a cooking class during his sophomore year and hopes to attend culinary school one day. He also took a part-time job stocking shelves at the local hardware store. Leo's pediatrician was pleased with his improved self-esteem and energy level. She asked Jamie: 'What is the end game? When is Dr Golden going to stop it?' That's an open question. Dr Golden has repeatedly advised Leo that he will probably have to take Wegovy for the rest of his life to maintain a healthy weight. Leo and his mother are OK with that. 'There is no end game,' Jamie told the pediatrician. Afraid of gaining it back FREDERICK, Maryland – Ms Stephanie Serrano didn't want to take a weight-loss drug. She didn't think it would work, and even if it did, she didn't like injections, especially if she had to get them for the rest of her life. But Ms Stephanie was desperate. At 320 pounds, she had already been diagnosed with type 2 diabetes and liver disease. She was tired of being the biggest kid in class and had become a virtual shut-in after years of failed dieting. 'Every doctor that I had ever seen would just tell me to eat healthier, like it was that simple,' Ms Stephanie said. In 2022, her family doctor referred the then-16-year-old to the obesity clinic at Children's National Hospital in Washington, DC. There, initial tests revealed that she had polycystic ovary syndrome, a common cause of weight gain in young women. 'That diagnosis changed everything,' she said. 'I wasn't lazy or not trying hard enough. My body was actually working against me.' In October that year, Ms Stephanie's doctor at Children's National, Dr Susma Vaidya, prescribed Ozempic, Novo's drug for type 2 diabetes with the same active ingredient as Wegovy, which hadn't yet been approved for teens. Ozempic has been widely used off-label for weight loss, both prior to Wegovy's launch and after due to shortages and spotty insurance coverage of the latter. By the time she saw Dr Vaidya, Ms Stephanie had her heart set on weight-loss surgery, swayed by TikTok videos of young adults showing their dramatic before-and-after transformations. 'Seeing how much they changed, it's incredible,' she said. 'So that's kind of what I wanted for my life. I wanted a permanent change.' Ms Stephanie Serrano lost weight by using Ozempic and undergoing bariatric surgery. PHOTO: REUTERS Dr Vaidya, medical director of the obesity clinic at Children's National, persuaded Ms Stephanie to accept a compromise: Ms Stephanie would give Ozempic a try while undergoing a six-month evaluation, including sessions with a dietician and a psychologist, to determine whether she was a good candidate for surgery, based on factors like adequate family support and eating regular, well-balanced meals. Ms Stephanie started taking the lowest recommended dose of Ozempic. The side effects were mild, though she occasionally experienced nausea and stomach pain after a big meal. She lost nine pounds in the first month. After four months, in February 2023, she was surprised – and pleased – that she had lost about 30 pounds. 'I had never seen the number on the scale go down,' she said. At that point, Dr Vaidya told Ms Stephanie she could continue taking the drug, or she could undergo surgery. Ms Stephanie's father, Jose, who was taking Ozempic for his type 2 diabetes, preferred that she stick with the drug. He worried about her risk of complications from a major operation. Ms Stephanie held firm. Despite her weight loss on Ozempic, she felt that surgery was the only way to end the isolation she had endured for years. Since the start of the Covid-19 pandemic, Ms Stephanie had retreated from school and friends. In 2021, during her sophomore year, her high school gave students the option to return or continue with online classes. She never went back to the classroom. Through the lens of social media, she watched classmates gloat about their beauty 'glow ups' and post photos of themselves with new makeup routines and outfits. MS Stephanie quit the school's Junior Reserve Officers' Training Corps, a leadership program sponsored by the US military, to avoid being around other people. 'I hid myself for those years,' she said. 'I no longer wanted to be a prisoner.' In April 2023, Ms Stephanie, at about 285 pounds, had gastric-sleeve surgery, which involved removing a large portion of her stomach to reduce food intake. She came through the surgery and recovery without complications. Today, the 19-year-old college freshman is down to about 175 pounds. She eats small meals and exercises regularly. Her diabetes is in remission, and her liver function is normal. She takes a full load of classes at a nearby community college and plans to transfer to a four-year university soon. She aspires to be a sports psychologist. As Ms Stephanie lost weight, she became more outgoing at school and in church and found she could make friends. She opened up to the possibility of a relationship and flirted with a young man at church. That didn't go anywhere, but she had surprised herself with her willingness to even try. 'Having a crush on anyone seemed so silly before. I could never imagine someone loving me,' she said. 'I was always ashamed of myself.' Amid all this progress, another problem emerged: Ms Stephanie was consumed with fear of gaining the weight back. She started skipping meals and guzzling energy drinks. After eating a small meal, she would run a mile to burn off the calories. Her legs and back began to ache, and she sometimes lost her balance – signs of possible muscle loss. Dr Vaidya told her, 'This is your body asking for protein.' Dr Vaidya diagnosed Ms Stephanie with an eating disorder in April 2024 and referred her to a hospital psychologist. Dr Vaidya also prescribed bupropion, an anti-depressant sometimes used to manage binge eating. The possibility that weight-loss drugs may put teens at risk of disordered eating is why some doctors urge rigorous screening of patients and continuous monitoring during treatment. Research on any association between weight-loss drugs or bariatric surgery and eating disorders is limited. Some small studies found that the use of GLP-1 drugs may decrease binge eating episodes among those who already had the disorder. But the studies only tracked patients for three to six months, leaving longer-term effects unknown. Ms Stephanie's psychologist urged her to stop counting calories and poring over the nutrition labels on packaged foods. She's making progress, but it's a 'constant battle,' she said. Stephanie still gives in sometimes to count calories, and when she exceeds her target, 'I completely shut down.' At home, Ms Stephanie does much of the cooking for her parents and older sister, Lily. She rarely eats what she cooks. At a recent dinner, her family enjoyed the carne asada, beans and pico de gallo she had prepared while she picked at a small bowl of rice and a homemade tortilla. She didn't finish either. Later, Ms Stephanie, her mother, Ms Vanessa Serrano, and Lily visited a local mall – a place she used to avoid because it was hard to find clothes her size there. At the American Eagle store, she tried on a pair of black jeans. She emerged hesitantly from the dressing room to have a look in a mirror. After Lily told her she looked incredible and snapped photos, Ms Stephanie checked herself out from several angles. She bought the jeans and wore them to church the next day. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.

AsiaOne

a day ago

• AsiaOne

Israeli attacks kill 44 Palestinians in Gaza, UN warns of water shortage, World News

CAIRO/GENEVA - Israeli fire killed at least 44 Palestinians in Gaza on Friday (June 20), many who were seeking food aid, local officials said, while the United Nations' children's agency said the scarcity of drinking water was at a crisis point. At least 25 people awaiting aid trucks were killed by Israeli action south of Netzarim in central Gaza, the Hamas-run local health authority said. The Gaza Humanitarian Foundation, which runs a month-old US-backed food distribution system, operates an aid site there, and aid trucks from other organisations including the UN also move through the area. Commenting on the incident, the Israeli military said troops fired warning shots at suspected militants who advanced in a crowd towards them. Israeli aircraft then fired a missile and "eliminated the suspects," it said in a statement. The military said it was aware that people other than the suspected militants were hurt and it was conducting a review. GHF said the incident did not occur at or near its distribution location. Separately, Gaza medics said at least 19 other people were killed in Israeli military strikes across the enclave on Friday, including 12 people in a house in Deir Al-Balah in central Gaza Strip. Meanwhile the UN's children's agency Unicef warned in Geneva that a shortage of fuel to operate wells and desalination plants in Gaza meant the enclave "is facing what would amount to a man-made drought." "Children will begin to die of thirst ... Just 40 per cent of drinking water production facilities remain functional," Unicef spokesperson James Elder told reporters. "We are way below emergency standards in terms of drinking water." Unicef so reported a 50 per cent increase in children aged six months to five years admitted for treatment of malnutrition from April to May in Gaza, and half a million people going hungry. Food aid In a statement, Hamas, which says Israel uses hunger as a weapon against Gaza's civiians, accused Israel of systematically targeting Palestinians seeking food. Israel denies this and contends Hamas steals aid, which the group denies. [[nid:719296]] In recent weeks, Israeli forces have repeatedly opened fire on Palestinians gathered at aid distribution points, resulting in dozens of civilian deaths and injuries. Humanitarian groups say the Gaza Humanitarian Foundation system forces people to risk their lives by entering combat zones to access food. Israel has said its actions were necessary to control crowds that posed a threat to its troops or to prevent breaches of restricted zones. But witnesses and human rights groups say many of the shootings appeared unprovoked and occurred without warning. Unicef said GHF was "making a desperate situation worse". GHF said in a statement on Thursday it had so far distributed nearly three million meals across three of its aid sites without incident. The Red Cross said the "vast majority" of patients that arrived at its Gaza field hospital during mass casualty incidents since the GHF aid system launched on May 27 had reported that they were wounded while trying to access aid at or around distribution points. The Gaza war was triggered when Palestinian Hamas militants attacked Israel on Oct 7, 2023, killing 1,200 people and taking 251 hostages, according to Israeli tallies. Israel's subsequent military assault on Gaza has killed nearly 55,700 Palestinians, according to Gaza's health ministry, while displacing almost the entire population of more than two million and causing a hunger crisis. Words561 oEmbed